Fusion Of Cells Patents (Class 435/449)
  • Patent number: 7189809
    Abstract: Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper ?-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo ?-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: March 13, 2007
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventor: Nobutaka Wakamiya
  • Patent number: 7148332
    Abstract: High affinity monoclonal antibodies for recognizing estrogen receptor (clone SP1) with immunohistochemistry and methods for creating such an antibody are disclosed. The lagomorph derived ER antibody provides a significant advantage over the currently available mouse ER antibodies in that there is no need for target retrieval when performing immunohistochemistry. Furthermore, the very low background when the lagomorph derived ER antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new ER (clone SP1) antibody had favorable results when compared to mouse monoclonal ER antibodies (clone 1D5). The lagomorph derived ER antibody may prove of great value in the assessment of ER status in human breast cancer. Humanized versions of the ER antibody may also provide therapeutic benefits.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: December 12, 2006
    Assignee: Spring Bioscience
    Inventors: Haiying Xia, Zhida Huang
  • Patent number: 7148040
    Abstract: The present invention relates to genetically altered hybridomas, myelomas and B cells. The invention also relates to utilizing genetically altered hybridomas, myelomas and B cells in methods of making monoclonal antibodies. The present invention also provides populations of hybridomas and B cells that can be utilized to make a monoclonal antibody of interest.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: December 12, 2006
    Assignees: University of Georgia Research Foundation, Inc., Abeome Corporation
    Inventors: Richard B. Meagher, Vince Laterza
  • Patent number: 7135556
    Abstract: We claim an isolated polypeptide having ability of binding with cholesterol. Said polypeptide is useful for investigating regulation of intestinal cholesterol absorption and cholesterol levels. Also, we claim a composition comprising said polypeptide bound to cholesterol or ezetimibe and a fusion protein comprising the polypeptide thereof.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: November 14, 2006
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
  • Patent number: 7129087
    Abstract: Coalescence of cells or other membrane-bound entities is facilitated by anchoring an outwardly projecting first oligonucleotide in one member and an outwardly projecting second oligonucleotide, complementary to the first, in a second member and incubating under hybridizing conditions. Liposomes may be coalesced with cells to deliver hydrophilic agents thereto, such as DNA probes or drugs. Kits containing complementary oligonucleotides containing hydrophobic anchoring moieties may be used.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: October 31, 2006
    Assignee: The Public Health Research Institute of the City of New York, Inc.
    Inventors: Fred R. Kramer, Osama A. Alsmadi, Sanjay Tyagi
  • Patent number: 7071372
    Abstract: An improved method of nuclear transfer employing long-term cultured somatic cells as the donor cells and enucleated oocytes as the recipient cells to produce dividing cybrids. Such cybrids are useful for developing viable animals clones when nurtured in a suitable host environment.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: July 4, 2006
    Assignees: University of Connecticut, The Governor of Kagoshima Prefecture
    Inventors: Xiangzhong Yang, Chikara Kubota
  • Patent number: 7053264
    Abstract: Methods and compositions for dedifferentiating nuclei from somatic cells are provided. Such methods and compositions are useful for facilitating processes such as, for example, cloning and immortalization of cells.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: May 30, 2006
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Elizabeth Wolffe, legal representative, Alan P. Wolffe, deceased
  • Patent number: 7045605
    Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: May 16, 2006
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Neil Bander, Francis J. Carr, Anita Hamilton
  • Patent number: 7045352
    Abstract: Detection of mutations associated with hereditary diseases is complicated by the diploid nature of mammalian cells. Mutations present in one allele are often masked by the wild-type sequence of the other allele. Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion. Nucleic acids from the hybrids can be analyzed for mutations in an unambiguous manner. This approach was used to detect two cancer-causing mutations that had previously defied genetic diagnosis. One of the families studied, Warthin Family G, was the first kindred with a hereditary colon cancer syndrome described in the biomedical literature.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: May 16, 2006
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Hai Yan
  • Patent number: 7029868
    Abstract: Methods of identifying inhibitors of the fusion of two types of cells, particularly when fusion is mediated by the interaction of a viral protein and such cellular proteins as CD4 and chemokine receptors, are disclosed. The methods are suitable for identifying substances that are useful for the treatment and prevention of viral diseases. Particularly preferred methods are useful for the identification of inhibitors of HIV-1 infection.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: April 18, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Kathleen A. Sullivan, Diana Benincasa, Margaret A. Cascieri, Lyndon J. Mitnaul, Lin-Lin Shiao, Michael R. Tota
  • Patent number: 7009040
    Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: March 7, 2006
    Assignee: Arius Research, Inc.
    Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay
  • Patent number: 6979534
    Abstract: The invention relates to methods of agglutinating or capturing cells comprising providing a mixture comprising a population of cells and a population of bacteriophage expressing a first antibody on the surface of the bacteriophage, the first antibody being specific for an antigen-bearing moiety expressed by at least a portion of the cells in the cell population, wherein the first antibody binds to the portion of the cells causing the bacteriophage to also bind to the portion of the cells, adding to the mixture a second antibody specific for the bacteriophage, wherein binding of the second antibody to bacteriophage bound to the portion of the cells causes the portion of the cells to agglutinate or be captured.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: December 27, 2005
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Donald L. Siegel
  • Patent number: 6956104
    Abstract: Provided is a protein used in the development of a therapeutic agent for neuron- or endocrine cell-related diseases, in which the transport system is involved. The protein has an amino acid sequence with one or more amino acids deleted, substituted, inserted or added relative to the amino acid sequence set forth under SEQ ID NO:1 in the Sequence Listing and which has a property to interact with GDP/GTP exchange factor II.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: October 18, 2005
    Assignees: JCR Pharmaceuticals Co., Ltd.
    Inventors: Susumu Seino, Tadao Shibasaki, Nobuaki Ozaki
  • Patent number: 6849451
    Abstract: A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiate, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: February 1, 2005
    Assignee: Greenville Hospital System
    Inventors: Thomas E. Wagner, Yanzhang Wei
  • Publication number: 20040259249
    Abstract: Disclosed are methods of creating a stem cell. Specifically described are methods of creating a pluripotent stem cell by reprogramming a differentiated cell. The method of creating the stem cell comprises the steps of obtaining a cytoplast from an existing embryonic stem cell; fusing the cytoplast with a differentiated cell to produce a cybrid; and culturing the cybrid to yield a pluipotent stem cell.
    Type: Application
    Filed: May 13, 2004
    Publication date: December 23, 2004
    Inventors: Nikolai Strelchenko, Yury Verlinski
  • Patent number: 6824983
    Abstract: The invention relates to a method for the mutagenesis of eucaryotic nucleotide sequences, preferably from plants, algae and/or fungi and a method for the production of genetically modified eucaryotic cells. The subject of the invention is the genetically altered nucleotide sequences of the type disclosed, vectors containing such nucleotide sequences, as well as genetically altered eucaryotic cells, tissue and/or parts of plants, algea and/or fungi and/or regenerated whole plants and the use thereof.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: November 30, 2004
    Assignees: BASF Plant Science GmbH, Albert-Ludwigs-Universitat Freiburg
    Inventors: Bodo Rak, Ralf Reski, Susanne Zimmermann, Marie-Christine Guitton, Elke Duwenig, Annette Freund
  • Patent number: 6805864
    Abstract: The present invention relates to a novel hybridoma cell line which secretes monoclonal antibodies capable of binding to the AT1 subtype of the Angiotensin II receptor. It also relates to monoclonal antibodies secreted by the hybridoma, which antibodies may be used in diagnostic test kits as well as having therapeutic applications.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: October 19, 2004
    Assignee: Queen Mary & Westfield College
    Inventors: Gavin Paul Vinson, Stewart Barker
  • Patent number: 6794494
    Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: September 21, 2004
    Assignee: Arius Research, Inc.
    Inventors: David S. F. Young, Susan E. Hahn
  • Patent number: 6783986
    Abstract: Proteins having the activity of saccharose phosphate synthetase (SPS) and a process for obtaining the same.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: August 31, 2004
    Assignee: Aventis Crop Sciences GmbH
    Inventors: Charles Van Assche, Danielle Lando, Jean Michel Bruneau, Toni Alois Voelker, Monica Gervais
  • Patent number: 6753171
    Abstract: A technique for controlling membrane denaturation reactions other than physical shear force was developed. For example, the present invention provides, a method for causing membrane disruption at a specific site by reacting a stimulus such as light with a compound that is activated by the stimulus, where the reaction occurs on a membrane such as a biomembrane. It also provides a membrane structure such as cells in which a specific site has been disrupted, which are obtained by the present method. Introduction of substances such as genes also became possible by using this membrane structure. Further provided is a membrane-destroying member for disrupting a membrane at a specific site. Thus, the present invention enabled, for example, easy membrane penetration using components constituting microelectrodes, micromanipulators, and microinjectors, which were conventionally hardly usable in penetrating cell membranes.
    Type: Grant
    Filed: December 28, 2000
    Date of Patent: June 22, 2004
    Assignee: Center for Advanced Science and Technology Incubation, Ltd.
    Inventors: Isao Karube, Takashi Saitoh
  • Patent number: 6740507
    Abstract: Recombinant cells which express a fluorescent holo-phycobiliprotein fusion protein and methods of use are described. The cells comprises a bilin, a recombinant bilin reductase, an apo-phycobiliprotein fusion protein precursor of the fusion protein comprising a corresponding apo-phycobiliprotein domain, and a recombinant phycobiliprotein domain-bilin lyase, which components react to form the holo-phycobiliprotein fusion protein. Also described are holo-phycobiliprotein based transcription reporter cells and assays, which cells conditionally express a heterologous-to-the-cell, fluorescent, first holo-phycobiliprotein domain.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: May 25, 2004
    Assignee: The Regents of the University of California
    Inventors: Alexander N. Glazer, Aaron J. Tooley, Yuping Cai
  • Patent number: 6733761
    Abstract: The present invention provides a purified and isolated nucleic acid encoding mycobacterial isocitrate lyase, as well as mutated forms of the nucleic acid. Further provided are purified and isolated isocitrate lyase proteins and mutated isocitrate lyase proteins. Additionally, the present invention provides vectors which comprises nucleic acid sequences encoding mycobacterial isocitrate lyase and mutated forms of this nucleic acid, as well as host cells containing these vectors. Also provided is a mycobacterium containing one or more mutations in its isocitrate lyase gene. Further provided by the present invention are agents that inhibit the activity or expression of a mycobacterial lyase protein, a method of identifying these, and a method of producing them. Finally, the present invention also provides a method of identifying genes required for persistence of mycobacteria.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: May 11, 2004
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: John D. McKinney, William R. Jacobs, Jr.
  • Patent number: 6652848
    Abstract: Immunostimulatory compositions that contain fused cells formed by fusion between dendritic cells and non-dendritic cells, methods of using these compositions, and methods of generating dendritic cell hybrids.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: November 25, 2003
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Jianlin Gong, Donald Kufe
  • Publication number: 20030199088
    Abstract: The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.
    Type: Application
    Filed: May 28, 2002
    Publication date: October 23, 2003
    Inventors: Roger A. Sabbadini, Neil Berkley, Mark W. Surber
  • Publication number: 20030199089
    Abstract: The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.
    Type: Application
    Filed: May 28, 2002
    Publication date: October 23, 2003
    Inventors: Mark W. Surber, Roger A. Sabbadini
  • Patent number: 6630327
    Abstract: This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for purifying hematopoietic stems cells expressing Pgp and diagnostic and therapeutic methods for cancer cells expressing Pgp.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: October 7, 2003
    Assignee: Board of Trustees of the University of Illinois
    Inventors: Eugene Mechetner, Igor B. Roninson
  • Publication number: 20030166279
    Abstract: The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.
    Type: Application
    Filed: May 28, 2002
    Publication date: September 4, 2003
    Inventors: Roger A. Sabbadini, Neil Berkley
  • Publication number: 20030049841
    Abstract: Provided is a method of screening or enriching a sample containing polynucleotides from a mixed population of organisms. The method includes creating a DNA library from a plurality of nucleic acid sequences of a mixed population of organisms and separating clones containing a polynucleotide sequence of interest on an analyzer detects a detectable molecule on a probe or bioactive substrate. The analyzer includes FACS devices, SQUID devices and MCS devices. The separated or enrich library can then be further process by activity based screening or sequence based screening. In addition, the enriched sequence can be compared to a database and to identify sequences in the database which have homology to a clone in the library thereby obtaining a nucleic acid profile of the mixed population of organisms.
    Type: Application
    Filed: October 10, 2001
    Publication date: March 13, 2003
    Inventors: Jay M. Short, Martin Keller, William Michael Lafferty
  • Patent number: 6531646
    Abstract: A method for the genetic modification and improvement of Porphyra species utilizing protoplast fusion is disclosed. The method of the invention features the use of conchoporangial branch conchocelis for at least one of the sources of protoplasts for protoplast fusion. Protoplasts produced from conchosporangial branch conchocelis of one species may be mixed with protoplasts produced from either blade material or conchocelis of a second species and fused using either a chemical fusing agent like polyethylene glycol (PEG) or electrofusion. Alternatively, an algal species other than a Porphyra species may be the second source of protoplasts. After fusion has occurred, fusion products are isolated and regenerated to whole plants or used as multicellular material.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: March 11, 2003
    Assignee: Northeastern University
    Inventors: Donald P. Cheney, Kathryn M. Roberts, Katherine L. Watson
  • Publication number: 20030040003
    Abstract: Detection of mutations associated with hereditary diseases is complicated by the diploid nature of mammalian cells. Mutations present in one allele are often masked by the wild-type sequence of the other allele. Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion. Nucleic acids from the hybrids can be analyzed for mutations in an unambiguous manner. This approach was used to detect two cancer-causing mutations that had previously defied genetic diagnosis. One of the families studied, Warthin Family G, was the first kindred with a hereditary colon cancer syndrome described in the biomedical literature.
    Type: Application
    Filed: August 2, 2002
    Publication date: February 27, 2003
    Applicant: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Hai Yan
  • Patent number: 6475794
    Abstract: Detection of mutations associated with hereditary diseases is complicated by the diploid nature of mammalian cells. Mutations present in one allele are often masked by the wild-type sequence of the other allele. Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion. Nucleic acids from the hybrids can be analyzed for mutations in an unambiguous manner. This approach was used to detect two cancer-causing mutations that had previously defied genetic diagnosis. One of the families studied, Warthin Family G, was the first kindred with a hereditary colon cancer syndrome described in the biomedical literature.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: November 5, 2002
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Hai Yan
  • Publication number: 20020115073
    Abstract: Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion event. Nucleic acids or proteins from the hybrids can be analyzed for polymorphisms to provide unambiguous determinations. Information thus obtained can be used to develop and implement personalized medical interventions for individuals having particular polymorphic markers.
    Type: Application
    Filed: February 16, 2001
    Publication date: August 22, 2002
    Inventors: Nickolas Papadopoulos, Hai Yan, Bert Vogelstein, Kenneth W. Kinzler
  • Publication number: 20020106796
    Abstract: An oncogene designated PAX8-PPAR&ggr;1 contains a PAX8 coding region fused to PPAR&ggr; coding region. Molecular characterization of PAX8-PPAR&ggr;1 molecules provides nucleotide and amino acid sequences useful for detection and treatment of certain tumors, particularly thyroid follicular carcinomas.
    Type: Application
    Filed: January 18, 2001
    Publication date: August 8, 2002
    Inventors: Jonathan A. Fletcher, Todd G. Kroll
  • Publication number: 20020076763
    Abstract: The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.
    Type: Application
    Filed: August 30, 2001
    Publication date: June 20, 2002
    Inventors: Nobuaki Hori, Claude Geoffrey Davis, Krisztina M. Zsebo, Aya Jakobovits
  • Publication number: 20020061590
    Abstract: The invention provides isolated nucleic acids molecules, designated MTP-1 nucleic acid molecules, which encode novel MTP-1-related transporter molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MTP-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an MTP-1 gene has been introduced or disrupted. The invention still further provides isolated MTP-1 proteins, fusion proteins, antigenic peptides and anti-MTP-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 14, 2001
    Publication date: May 23, 2002
    Inventors: Maria Alexander Glucksmann, Rory A.J. Curtis
  • Patent number: 6387698
    Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: May 14, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
  • Publication number: 20020041868
    Abstract: The invention is concerned with fusions of dendritic cells and antigen presenting cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy. The fusions according to the invention can also be used in methods for antigen discovery.
    Type: Application
    Filed: February 12, 2001
    Publication date: April 11, 2002
    Inventors: Charles Nicolette, Bruce L. Roberts, Jianlin Gong, Donald Kufe
  • Publication number: 20020042127
    Abstract: Disclosed is a cell which expresses a surface marker associated with a professional antigen presenting cell, and a fusogenic membrane protein, where the cell may also express at its surface a tumor cell marker. Also disclosed is a fusion hybrid formed by the fusion of a tumor cell and a professional antigen presenting cell (APC) such that the resulting fusion hybrid expresses an APC marker, a tumor cell marker, and a fusogenic membrane glycoprotein. Also disclosed are compositions comprising the cells and fusion hybrids, and methods of making and using the hybrids.
    Type: Application
    Filed: November 22, 1999
    Publication date: April 11, 2002
    Inventors: STEPHEN JAMES RUSSELL, RICHARD VILE, ANDREW BATEMAN, ALAN MELCHER
  • Publication number: 20020031521
    Abstract: The present invention relates to a method of of transferring genomic DNA from apoptotic bodies to engulfing cells, wherein DNA is transferred from a donor cell to a recipient cell. More specifically the method includes providing somatic donor cells comprising desired DNA; generating apoptotic bodies of said donor cells; incubation of the apoptotic bodies with engulfing recipient cells under biological conditions allowing uptake of DNA from the apoptotic bodies by said recipient cells; and optionally selecting recipient cells which have integrated DNA from the apoptotic bodies. The present method is useful in various pharmaceutical applications, such as in vaccine preparations and gene identification procedures.
    Type: Application
    Filed: April 26, 2001
    Publication date: March 14, 2002
    Inventors: Anna-Lena Spetz-Holmgren, Lars Holmgren, Jan Andersson, Judah Folkman
  • Patent number: 6355485
    Abstract: A new and useful apparatus for producing cell electrofusion is provided. The apparatus comprises: a. a chamber with a substrate disposed therein, b. means for directing the cells to be fused toward one side of the substrate; and c. a device for inducing fusion of the portion of the cells.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: March 12, 2002
    Assignee: University of South Florida
    Inventors: Mark J. Jaroszeski, Richard A. Gilbert, Richard Heller
  • Patent number: 6348576
    Abstract: The invention provides a human cornichon protein (CORN) and polynucleotides which identify and encode CORN. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating and preventing disorders associated with expression of CORN.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: February 19, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
  • Publication number: 20020001842
    Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.
    Type: Application
    Filed: December 15, 2000
    Publication date: January 3, 2002
    Inventor: Karen B. Chapman
  • Publication number: 20010049142
    Abstract: A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiate, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.
    Type: Application
    Filed: January 9, 2001
    Publication date: December 6, 2001
    Inventors: Thomas E. Wagner, Yanzhang Wei
  • Patent number: 6322787
    Abstract: According to the invention, there is provided a human or animal cell expressing an antibody directed against a surface antigen on an antigen-presenting cell (APC) and lacking parental tumor-derived immunoglobulin.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: November 27, 2001
    Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbH
    Inventors: Ralph Mocikat, Horst Lindhofer
  • Patent number: 6306626
    Abstract: The present invention provides an anti-IgM antibody conjugate comprising: a monoclonal antibody which binds selectively to IgM antibody, does not bind to IgG1 or IgG2 antibody, and has a G isotype; and a cytotoxic moiety conjugated to said monoclonal antibody. The present invention also provides a method for collecting hybridoma producing IgG isotype monoclonal antibodies comprising: treating a hybrid cell population with a monoclonal antibody which has a G isotype and binds selectively to IgM antibody but does not bind to IgG1 or IgG2 antibody; subjecting said resulting immuncomplexed cells to sorting; and collecting the cells which have not complexed with said antibodies.
    Type: Grant
    Filed: February 7, 1994
    Date of Patent: October 23, 2001
    Assignee: Research Development Foundation
    Inventors: Michael G. Rosenblum, Nicholas J. Donato
  • Publication number: 20010012632
    Abstract: A method produces an anti-tumor response in a mammalian subject in need of anti-tumor treatment. Hybrids of tumor cells with dendritic cells or dendritic-like cells can be administered to the subject. The tumor cell of the hybrid corresponds to the tumor of the subject. Alternatively, autologous immune cells of the subject can be administered in which the immune cells are activated in vitro by co-cultivation with these hybrids.
    Type: Application
    Filed: March 9, 2001
    Publication date: August 9, 2001
    Inventors: Muriel Moser, Oberdan Leo, Laurence Lespagnard, Jacques Urbain, Catherine Bruyns, Catherine Gerard, Michel Goldman, Thierry Velu, Fabienne Willems, Nicole Tasiaux, Jason Perret, AnneMarie Verheyden
  • Patent number: 6258564
    Abstract: The invention is related to antibodies which specifically react with connective tissue type-human mast cells, a production method of the antibodies, hybridomas which produce the antibodies, a production method of the hybridomas and antigen proteins recognized by the antibodies. After cord blood cells were cultured in the presence of SCF and IL-6, they were further cocultured with primary culture of human skin fibroblasts, and connective tissue type-human mast cells were thus obtained. A rat was immunized using the cells, hybridomas were prepared and selected by an ordinary method, and novel monoclonal antibodies were harvested from the culture supernatant of the selected hybridomas. The monoclonal antibodies specifically reacted with connective tissue type-human mast cells.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: July 10, 2001
    Assignee: Medical & Biological Laboratories Co., Ltd.
    Inventors: Makoto Kawai, Tadashi Okada, Fukiko Atsumi
  • Patent number: 6218188
    Abstract: The subject invention concerns materials and methods useful in the control of pests and, particularly, plant pests. More specifically, the subject invention provides plant-optimized, polynucleotide sequences that encode pesticidal toxins (full-lengthand truncated). Truncated polynucleotide sequences can be used to produce truncated toxins or for the production of fusion (or chimeric) genes and proteins. The polynucleotide sequences of the subject invention have certain modifications, compared to wild-type sequences, that make them particularly well-suited for optimized expression in plants. Using techniques known to those skilled in the art, the polynucleotide sequences described herein can be used to transform plants in order to confer pest resistance upon the plants.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: April 17, 2001
    Assignee: Mycogen Corporation
    Inventors: Guy A. Cardineau, Steven J. Stelman, Kenneth E. Narva
  • Patent number: 6197297
    Abstract: A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18, 500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose.
    Type: Grant
    Filed: November 15, 1995
    Date of Patent: March 6, 2001
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Toshio Kunikata, Mutsuko Taniguchi, Keizo Kohno, Masashi Kurimoto
  • Patent number: 6174726
    Abstract: The invention is directed to a method for the preparation of a conditionally immortalized immortalization-helper cell (fuseme), the fusemes generated by said method, hybridoma cells prepared using said fusemes as well as a method for immortalization of mammalian cells using said fuseme cells. Further, the invention relates to the generation of T cells directed agaist tumor cells using a fuseme cell.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: January 16, 2001
    Assignee: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH
    Inventors: Martin Staege, Georg Bornkamm, Bettina Kempkes